Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  10/16/2009
 
Trade Name:  CERVARIX
 
Generic or Proper Name (*):  Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant*
 
Indications Studied:  Prevention of genital warts caused by HPV 16 and 18
 
Therapeutic Category:  Preventive Vaccine
 
Ages Studied:  15-25 years
 
Study #:  4
 
Study Type:  Efficacy/Safety/Immunogenicity
 
Study Design:  Double-blind/Controlled
 
No Centers:  135
 
No Countries:  14
 
BPCA(B), PREA(P):  P
 
-
-